Drug Trial Radar · NCT00996736
Mycotic Ulcer Treatment Trial I
Last checked: Nov 19, 2026Latest source record: Aug 1, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
323
Actual
Start
Apr 2010
Primary completion
Jul 2012
Study completion Jul 2012
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Aravind Eye Hospitals, India; Dartmouth-Hitchcock Medical Center; National Eye Institute (NEI)
- First posted
- Oct 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if natamycin or voriconazole results in better visual outcomes in fungal corneal ulcers, especially visual acuity.
Conditions
- Corneal Ulcer
- Eye Infections, Fungal
Interventions
NatamycinDrug
5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks after enrollment.
VoriconazoleDrug
1% voriconazole plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best Spectacle-corrected logMAR Visual AcuityTime frame: 3 months from enrollment
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Proctor Foundation, UCSF
San Francisco, California
Aravind Eye Hospitals
Madurai, Tamil Nadu, India
Aravind Eye Hospital
Pondicherry, Tamil Nadu, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.